Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Early Pipeline Case Study

- PMLiVE

Novartis picks up inclisiran after completion of MedCo acquisition

If approved could become blockbuster cholesterol treatment

- PMLiVE

Keytruda doesn’t extend survival in small cell lung cancer

Unlikely to extend use into the first-line setting

- PMLiVE

EU, US biotechs merge to create fibrosis, cancer player

New company will be headquartered in Copenhagen, Denmark

- PMLiVE

Merck KGaA, Pfizer’s Bavencio improves survival in bladder cancer

Confirmatory trial strengthens claim in therapy area

- PMLiVE

Merck strengthens KRAS stake with Taiho and Astex partnership

Partner companies could gain $2.5bn in milestone payments

- PMLiVE

Green Valley’s algae-based Alzheimer’s drug to undergo global clinical trials

Gained conditional approval in China in November

AstraZeneca AZ

AstraZeneca’s heart failure drug Farxiga scores FDA priority review

Approval in HFrEF would significantly expand drug's reach

- PMLiVE

NICE rejects Akcea’s rare inherited disorder drug Waylivra

Draft guidance deems drug too costly for NHS use

- PMLiVE

GSK divests travel vaccines to Bavarian Nordic as part of strategic refocus

Agreed divestment deal is worth up to €955m

- PMLiVE

GSK, Pfizer and Sanofi among drugmakers planning price hikes in US

Pricing pressures increase amid intense political scrutiny

- PMLiVE

Antibiotic biotech Melinta files for bankruptcy

Worries over antibiotic business model continue to mount

- PMLiVE

NICE knocks back Roche’s Tecentriq for small cell lung cancer

Insufficient evidence to approve use in SCLC on the NHS

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links